SCHEMBL310145

SCHEMBL310145

CCOc1cc(C2CCN(CCS(C)(=O)=O)CC2)ccc1NC(=O)C(F)(F)F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
INSR P06213 1/20 0.44
IGF1R P08069 1/20 0.44
CCR5 P51681 6/20 0.43
KIT P10721 2/20 0.42
NTRK1 P04629 1/20 0.42
LCK P06239 1/20 0.42
CSF1R P07333 1/20 0.42
AXL P30530 1/20 0.42
FLT3 P36888 1/20 0.42
CAMK2D Q13557 1/20 0.42
DRD2 P14416 2/20 0.39
DRD1 P21728 1/20 0.39
DRD4 P21917 1/20 0.39
DRD5 P21918 1/20 0.39
DRD3 P35462 1/20 0.39
TLR9 Q9NR96 2/20 0.39
TLR8 Q9NR97 2/20 0.39
TLR7 Q9NYK1 2/20 0.39
SIGMAR1 Q99720 1/20 0.38
MMP2 P08253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10290737 0.84 CCR5 (0.41) CCR5CAMK2DDRD2FLT4PTK2
SCHEMBL10257451 0.83 CAMK2D (0.40) IGF1RCCR5CAMK2DDRD2DRD4
SCHEMBL13226155 0.79 ALK (0.42) CSF1RCAMK2DTLR9TLR8TLR7
SCHEMBL310804 0.79 DRD2 (0.46) CCR5KITDRD2DRD3TLR9
Acetic Acid SCHEMBL310269 0.77 BRD4 (0.41) CCR5CSF1RCAMK2DTLR9TLR8
SCHEMBL3167693 0.76 CSF1R (0.50) KITNTRK1LCKCSF1RAXL
SCHEMBL310503 0.76 ALK (0.46) INSRFLT3DRD2DRD4DRD3
SCHEMBL311689 0.70 TLR9 (0.47) KITDRD2TLR9TLR8TLR7
SCHEMBL18764021 0.68 EGFR (0.49) IGF1RCCR5CAMK2DTLR9TLR8
SCHEMBL4573714 0.66 DRD2 (0.49) DRD2TLR9TLR8TLR7SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2162454-B1 IMIDAZOPYRIDINE KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-01-02 EP disclosed
EP-2162454-B1 IMIDAZOPYRIDINE KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-01-02 EP disclosed
US-8093239-B2 Imidazopyridine kinase inhibitors GLAXOSMITHKLINE LLC (US) 2012-01-10 US disclosed
US-20100216779-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2010-08-26 US disclosed
US-20080300242-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2008-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300242-A1 Imidazopyridine Kinase Inhibitors ABL1, MAP3K19, MAP3K5 INSR 814/4885IGF1R 633/4885CCR5 1263/4885
US-20100216779-A1 Imidazopyridine Kinase Inhibitors ABL1, MAP3K19, MAP3K5 INSR 814/4885IGF1R 633/4885CCR5 1263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.